Assignee
SHANGHAI EPIMAB BIOTHERAPEUTICS CO LTD
CN·2 granted patents·5 pending applications·4 citations·filing 2019–2022
Top patents by PatentIndex Score
7 records- 0179US12060425B2High affinity antibodies to PD-1 and LAG-3 and bispecific binding proteins made therefromSHANGHAI EPIMAB BIOTHERAPEUTICS CO LTD·Filed 2019·Granted Aug 13, 2024·4 cites·21 claims
- 0253US2025002594A1Anti-cd122 antibodies, anti-cd132 antibodies, and related bispecific binding proteinsSHANGHAI EPIMAB BIOTHERAPEUTICS CO LTD·Filed 2022·Application pending·0 cites
- 0352US2025282881A1Antibodies and bispecific binding proteins that bind ox40 and/or pd-l1SHANGHAI EPIMAB BIOTHERAPEUTICS CO LTD·Filed 2022·Application pending·0 cites
- 0446US12516133B2TGFβ/PD-L1 bispecific binding proteinsSHANGHAI EPIMAB BIOTHERAPEUTICS CO LTD·Filed 2020·Granted Jan 6, 2026·0 cites·13 claims
- 0544US2023002489A1Antibodies to cd3 and bcma, and bispecific binding proteins made therefromSHANGHAI EPIMAB BIOTHERAPEUTICS CO LTD·Filed 2020·Application pending·0 cites
- 0643US2022389111A1High affinity antibodies to cd39 and uses thereofSHANGHAI EPIMAB BIOTHERAPEUTICS CO LTD·Filed 2019·Application pending·0 cites
- 0741US2022017617A1Efficiently expressed egfr and pd-l1 bispecific binding proteinsSHANGHAI EPIMAB BIOTHERAPEUTICS CO LTD·Filed 2019·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when SHANGHAI EPIMAB BIOTHERAPEUTICS CO LTD files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →